Cipla reported INR71.19B in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Arca Biopharma 0 0 Mar/2025
aTyr Pharma USD 2.29M 107.78M Mar/2026
Bio Path 0 0 Mar/2025
Brainstorm Cell Therapeutics 0 0 Mar/2025
Capricor Therapeutics USD 11.13M 8.87M Dec/2024
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cipla INR 71.19B 5.78B Jun/2026
Dr.Reddys Laboratories INR 80.71B 5.25B Jun/2026
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sun Pharmaceuticals INR 153B 7.14B Jun/2026
TherapeuticsMD USD 234K 79K Jun/2024
UPL INR 101.81B 81.54B Jun/2026